

1 **Protocol for a randomized controlled trial of the Breaking Free Online Health and Justice program**
2 **for substance misuse in prison settings**

3

4 **Abstract**

5 **Background:** Substance misuse, including problematic drug and alcohol use, are significant issues in
6 society that can have multiple detrimental effects. Many people access support for their substance
7 misuse during prison sentences, due to the associations between substance misuse and offending,
8 and the high proportion of the prison population who have drug and alcohol issues. Breaking Free
9 Online Health and Justice is a computer-assisted therapy program that has been developed to support
10 substance-involved offenders to address their substance misuse and associated offending within
11 prison settings. **Methods:** This will be a parallel-group randomized controlled trial of 4-week Breaking
12 Free Online Health and Justice program as an adjunct to standard treatment for substance misuse, in
13 comparison to standard treatment only, in a male Category D open prison. Interventional and control
14 groups will be compared in terms of the changes in their scores on multiple measures from baseline
15 to post-treatment assessment at 4-weeks, and then 3- and 6-months follow-up. Participants will be
16 adult male offenders serving sentences in prison in England who have demonstrable difficulties with
17 drugs and/or alcohol for at least the past 12-months. The primary outcome measure will be self-
18 reported substance misuse, with secondary outcomes being standardized psychometric assessments
19 of substance dependence, mental health, biopsychosocial functioning, quality of life and post-release
20 offending. Other secondary measures will include frequency of completion of specific intervention
21 strategies in the program. **Discussion:** This study will examine whether Breaking Free Online Health
22 and Justice as an adjunct to standard substance misuse interventions in prisons, improves outcomes
23 for substance-involved offenders receiving interventions in custodial settings. Findings from the study
24 will be used to inform further developments of the program and potential improvements to custodial
25 treatment.

26

27 **Trials registration:** [ISRCTN09846981](https://www.isrctn.com/ISRCTN09846981)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Keywords: Substance misuse; alcohol; drugs; computer-assisted therapy; recovery; prisons; criminal justice

Background

Substance misuse, including problematic drug and alcohol use, are significant issues in society that can have multiple detrimental effects. Substance misuse is implicated in a number of criminal offences, including acquisitive crime (Comiskey, Stapleton, & Kelly, 2012; Hayhurst et al., 2013), anti-social and violent behavior (Boden, Fergusson, & Horwood, 2012; Lundholm, Haggård, Möller, Hallqvist, & Thiblin, 2013), domestic and intimate partner violence (Stuart et al., 2008; Wilson, Graham, & Taft, 2017) and child neglect (Solis, Shadur, Burns, & Hussong, 2012). Links between substance use and criminal behavior are identified within the research literature (Bennett, Holloway, & Farrington, 2008; Hough, 2002; Schroeder, Giordano, & Cernkovich, 2007). Levels of crime reported by substance users during periods of use (Ball, Shaffer, & Nurco, 1983; Bennett & Holloway, 2009; Bennett et al., 2008; Best, Sidwell, Gossop, Harris, & Strang, 2001; Goldstein, 1985; Gossop, Marsden, Stewart, & Rolfe, 2000; Inciardi, 1979; McGlothlin, Anglin, & Wilson, 1978), and the high proportion of the prison population who are substance misusers (Budd, Collier, Mhlanga, Sharp, & Weir, 2005; Jones et al., 2007; Phillips, 2000; Young, Wells, & Gudjonsson, 2011) all indicate that substance misuse and offending often co-occur and that substance misuse is a primary “criminogenic” factor (Weekes, Moser, & Langevin, 1999).

In the 2016 Crime Survey for England and Wales, 8.4% of 16 – 59 year old participants living in the UK reported using an illicit drug within the last 12-months, which, if representative, would extrapolate to approximately 2.7 million people (Home Office, 2016). The economic costs to society of substance misuse are substantial, with problematic alcohol misuse alone being estimated to have cost £ 47 billion in 2016 (PHE, 2016). Recent data reported by Public Health England from the National Drug Treatment Monitoring System demonstrate that overall, 279,793 adults were in contact with drug and alcohol

1 services between 2016 and 2017 (PHE, 2017), with 26% of those receiving treatment for opiate
2 dependence being referred into treatment by criminal justice services. Furthermore, up to 48% of
3 those seeking treatment for both opiate and 'novel psychoactive substance' dependence were
4 referred via the criminal justice system (PHE, 2017). And additionally, a recent systematic review
5 which included studies from multiple countries, found that both alcohol use disorder and substance
6 use disorder are highly prevalent amongst the prison population, with pooled prevalence estimates
7 of each being 24% and 51% respectively (Fazel, Yoon, & Hayes, 2017).

8

9 Given the significant associations between substance use and offending, it seems intuitive that if any
10 intervention for substance-involved offenders is to be effective, it needs to address not only the
11 substance use but also the offending behavior that may be associated with it (Elison, Davies, et al.,
12 2017). In order to meet this requirement, Breaking Free Online (BFO) Health and Justice, a computer-
13 assisted therapy (CAT) program designed to address both substance misuse and offending behaviors
14 simultaneously, has been developed. Such CAT approaches have the potential to widen access to
15 evidence-based treatment for substance misusing individuals as they can be delivered at scale, and
16 because intervention content is delivered via a computer in a highly standardized way, CAT can
17 enhance treatment fidelity and thus treatment effectiveness (Bickel, Marsch, Buchhalter, & Badger,
18 2008; Moore, Fazzino, Garnet, Cutter, & Barry, 2011).

19

20 This criminal-justice specific version of BFO has been developed via modification of a version of the
21 program that has been delivered in community-based substance misuse treatment settings for the
22 past eight-years. Published research informed by guidance by the UK Medical Research Council (MRC)
23 around the development and evaluation of complex interventions (Craig et al., 2008; Moore et al.,
24 2015) has examined the evidence-base underpinning the clinical content of BFO (Dugdale, Ward, et
25 al., 2016), and barriers and facilitators of the implementation of the program in real-world treatment
26 settings (Dugdale, Elison, Davies, Ward, & Dalton, 2017; Dugdale, Elison, Ward, Davies, & Dalton, 2016;
27 Elison, Ward, Davies, & Moody, 2014; Ward, Davies, Dugdale, Elison, & Bijral, 2017). Research

1 examining the effectiveness of the program (Elison, Davies, & Ward, 2015a, 2015b; Elison, Ward,
2 Davies, Lidbetter, et al., 2014; Elison, Ward, et al., 2017) has demonstrated significant reductions in
3 substance dependence and use, and significant improvements in mental health and broader
4 psychosocial functioning. Examination of the mechanisms of action of BFO has demonstrated that
5 users follow tailoring advice provided by the program, that the program exhibits a ‘dose-response’,
6 and that completion of cognitive restructuring strategies in the program underpins changes to broader
7 biopsychosocial functioning (Elison, Jones, Ward, Dugdale, & Davies, 2017).

8

9 Since 2015 BFO has been available in prisons in addition to community settings via the ‘Virtual
10 Campus’ (VC), the UK prisons IT infrastructure that allows offenders to access a limited range of online
11 programs to support their education, training and employment. However, BFO has become the first
12 *healthcare* program to be included on VC, and the first digital intervention for offenders to be
13 accredited by the Ministry of Justice Correctional Services Advice and Accreditation Panel. Mixed-
14 methods research conducted by the authors explored both the barriers and facilitators of
15 implementation of BFO in prison settings (Elison, Weston, Davies, Dugdale, & Ward, 2015; Elison,
16 Weston, Dugdale, Ward, & Davies, 2016), and also examined clinical outcomes for offenders accessing
17 the program as part of the ‘Gateways’ through-care initiative (Davies et al., 2017), which aimed to
18 support substance-involved offenders as they transition back to the community.

19

20 Qualitative interview data from 16 offenders engaging with BFO and 10 members of prison staff
21 supporting them suggested that both offenders and staff were able to overcome initial anxieties about
22 using digital technology. Offenders reported the program supported them to develop coping skills to
23 enable them to remain abstinent from using drugs and alcohol, and therefore reduce their chances of
24 reoffending when they were released (Elison, Weston, et al., 2015). Staff reported that they felt the
25 program provided an opportunity for offenders to access an evidence-based intervention to allow
26 them to work on their drug and alcohol difficulties, and also provided an opportunity to use the VC in
27 a novel way to further support offender rehabilitation (Davies et al., 2017). Analyses of quantitative

1 clinical outcomes from a sample of 151 male offenders accessing BFO before being released from
2 prison (Davies et al., 2017; Elison, Weston, et al., 2015), demonstrated significant reductions in alcohol
3 and drug dependence and consumption, significant improvements in quality of life, and significant
4 improvements in multiple aspects of broader biopsychosocial functioning. However, only within-
5 subject analyses were conducted in this research, with no 'standard treatment' control group having
6 been included in the research conducted to date.

7

8 **Method**

9 **Aims**

10 This study will evaluate, via a randomized controlled trial (RCT) methodology, the efficacy of BFO
11 within a criminal justice population. The principle aim of this study is to determine the effectiveness
12 of BFO when delivered alongside standard treatment, compared to standard treatment only, in
13 reducing alcohol and drug consumption and dependence, and any possible impact on mental health
14 and broader biopsychosocial functioning. It is anticipated that delivery of BFO alongside standard
15 treatment should confer some added benefits to participants engaging with this novel intervention,
16 when compared to participants engaging with standard treatment only. This means there may be
17 some post-treatment differences between the two study groups in terms of substance-related
18 outcomes and broader biopsychosocial functioning.

19

20 **Design**

21 This will be a randomized, parallel-group longitudinal comparison study of 4-week periods of either i)
22 BFO plus standard treatment, or ii) standard treatment only, using intention to treat (ITT) analyses to
23 examine outcomes.

24

25 **Setting**

26 The study will be conducted in an adult male prison in North-West England, UK. This prison is a
27 'Category D' open prison where offenders are, subject to approval, provided with 'Release on

1 Temporary License' (ROTL) where they are granted release to work in the community or have 'home
2 leave'. This prison is a resettlement prison which has an operational capacity of just over 600 male
3 offenders, approximately a quarter of whom are either on life sentences or subject to indeterminate
4 sentences. Approximately, 75% of the men in the prison are serving sentences of 4-years or longer at
5 any one time. Around three-quarters of the men in the prison are over the age of 30 years, and around
6 40% have identified substance misuse difficulties. The prison places a strong emphasis on
7 rehabilitation and community reintegration, running a range of vocational training courses, alongside
8 initiatives to support the men serving sentences in the prison to maintain and enhance the
9 relationships they have with their families.

10

11 This category of prison has been chosen for the study because, although even the very highest security
12 prisons in the UK have significant issues with drug and alcohol use, offenders in a Category D prison
13 may potentially have the most opportunity to use substances, as they spend some of their time in the
14 community. Most participants may be on ROTL during the study, including resettlement day release,
15 and resettlement overnight release, so it is more likely that outcomes related to substance use will be
16 an artifact of treatment effects, rather than lack of opportunity to use substances due to incarceration
17 in a highly secure environment. Although it is anticipated that most, if not all, participants will be
18 receiving ROTL during the study, the ROTL status of each participant will be recorded during their first
19 treatment session and this will be taken into account during data analyses, if there are a significant
20 number of participants not provided with ROTL during the study. Participants will be recruited from
21 standard alcohol and drug misuse services in the prison, which are delivered in coordination with Her
22 Majesty's Prison and Probation Service (HMPPS).

23

24 **Participants**

25 Participants included in the study will be offenders currently serving a prison sentence aged 18 to 65
26 years with problem alcohol and/or drug use of duration of 12-months or longer. This period of time is
27 in line with DSM-V criteria for substance related disorders (American Psychiatric Association, 2000). It

1 is estimated that a total of 240 participants will need to be recruited and screened in order to obtain
2 a sample of 120 evaluable participants (see 'Power Calculation').

3

4 - Inclusion criteria

5 1. Male offenders currently serving a prison sentence with problem alcohol and/or drug use aged
6 18 to 65 years.

7 2. Willing and able to give informed consent for participation in the study.

8 3. Has at least 4-months left to serve of their sentence at the prison acting as the research site,
9 at the time they are recruited to the study.

10 4. Problem alcohol and/or drug use present for more than 12-months.

11 5. Willing to follow a treatment for problem alcohol and/or drug use for 4-weeks.

12 6. Willing to provide outcome measures at 3- and 6-months follow-up.

13 7. Concomitant alcohol and drug/s use permitted, as well as any prescribed medication.

14

15 - Exclusion Criteria

16 1. Participation in any other alcohol and/or drug related clinical studies.

17 2. Participant receiving standard treatment for alcohol and/or drug misuse at the time of
18 recruitment into the study.

19 3. Individuals detained under the Mental Health Act.

20 4. Individuals with a known and diagnosed intellectual or developmental disability.

21 5. Non-English speaking offenders (study information material and program only produced in
22 English).

23

24 **Interventions**

25 **Breaking Free Online Health and Justice**

1 BFO is an online treatment program for substance-involved offenders. Clinical content of BFO has been
2 informed by the available evidence-base around effective biopsychosocial and behavioral intervention
3 approaches for addressing drug and alcohol misuse (National Treatment Agency for Substance Misuse,
4 2006a, 2006b; NICE, 2007, 2011, 2012), including cognitive-behavioral principles (Beck, 1993; Beck,
5 Wright, Newman, & Liese, 2011), and other approaches including mindfulness-based relapse
6 prevention (Marlatt, Bowen, Chawla, & Witkiewitz, 2010; Marlatt & Donovan, 2005).

7

8 When an individual first uses BFO, they complete a psychometric assessment developed by the
9 authors, the 'Recovery Progression Measure' (RPM: Elison, Davies, & Ward, 2016), which is contained
10 within the program. The RPM measures baseline levels of functioning, and treatment-related changes
11 in functioning, across six domains; 'negative thoughts', 'emotional impact', 'unhelpful behaviors',
12 'difficult situations', 'physical sensations', and 'lifestyle'. Date generated via completion of the RPM is
13 then utilized by the BFO program to populate a visual depiction of a six-domain biopsychosocial model,
14 the 'Lifestyle Balance Model' (LBM: Davies, Elison, Ward, & Laudet, 2015), which forms the theoretical
15 underpinnings of the program and is based on the five-factor model used in cognitive behavioral
16 therapy (Greenberger & Padesky, 1995; Williams & Chellingsworth, 2010). The LBM (see Figure 1) acts
17 as a clinical formulation to help the user understand the domains of their functioning that may be
18 implicated in their substance misuse.

19

20 Based on RPM scores, each of the six domains of the visual depiction of the LBM are colored either
21 green, amber or red. This 'traffic light' system indicate respectively, 'little', 'moderate' or 'significant'
22 impairment in each of the six domains. Tailored advice then guides the user to concentrate on
23 completing intervention strategies contained in the program that are aligned to domains of
24 functioning in the LBM where they may be experiencing the greatest levels of impairment (amber and
25 red domains of the LBM). However, users are also encouraged to complete and interventions within
26 green areas to help build long-term resilience.

27

1 Table 1 provides an overview of the clinical content of BFO and the theoretical underpinnings of
2 individual intervention strategies within the program. Table 1 maps the clinical content of BFO onto
3 individual behavior change techniques (BCTs) from the BCT taxonomy (V1) (Dugdale, Ward, et al.,
4 2016; Michie, Hyder, Walia, & West, 2011). The BCT taxonomy (V1) provides a standardized means of
5 describing the clinical content of complex behavioral change interventions (Michie et al., 2011).

6
7 TABLE 1 HERE
8

9 The BFO program has been designed to be used by individuals as either a stand-alone or adjunct
10 treatment program alongside standard treatment, and as either self-help or as CAT with support by
11 practitioners, keyworkers, peer-mentors or other supporters. Consultation with HMPPS has ensured
12 that all intervention strategies in the program are appropriate for the prison setting and comply with
13 HMPPS quality assurance, security and information assurance processes. For this study, the BFO
14 program will be comprised of 8 sessions which will be run over 4-weeks, with two sessions held each
15 week.

16

17 **Standard treatment**

18 Both study groups will receive standard treatment as part of the study design. It is expected that there
19 will be a degree of heterogeneity within both the BFO and control groups in terms of the 'standard
20 treatment' each participant receives. Information regarding the specific standard treatments each
21 participant receives will be collected, including the specific standard treatments each participant
22 receives, the number of sessions completed, what kind of practitioner has delivered it, and also the
23 medications each participant may have been prescribed during the course of the study (see Appendix
24 B). These data will allow comparisons to be made between different control treatments.

25

26 In terms of the psychosocial and behavioral support treatments available in prisons, low-intensity
27 group-based interventions are usually delivered by key-workers in alcohol and drug misuse services

1 and include techniques such as motivational interviewing and contingency management. These group-
2 based interventions will be delivered with groups of participants that are of a similar size to the group
3 sessions of BFO, i.e. groups of 10 participants. In order to avoid violation of the stable unit treatment
4 value assumption, participants in the BFO group will receive their group-based standard treatment in
5 groups that are run separately from the group-based standard treatments the control group receive.

6

7 More formal psychological therapies are usually delivered by specialist psychological therapists
8 through CBT based interventions and are delivered on a one-to-one basis. All standard treatment
9 sessions have a duration range of 30-60 min and take place once or twice a week for a period of
10 approximately 4 – 12 weeks. The number of interventions each participant will receive may vary.
11 During treatment concomitant alcohol and drug/s use may be permitted, as well as any prescribed
12 medication (detoxification included).

13

14 **Procedure**

15 Site investigators and practitioners working in the prison substance misuse service will inform
16 participants of the study. Site investigators will be responsible for completing screening, consent and
17 randomization. Site investigators and practitioners will be responsible for conducting baseline and 4-
18 week post-baseline assessments. Practitioners will be responsible for delivering both BFO and the
19 standard treatments received by the two study groups. Site investigators will be responsible for
20 conducting 3- and 6-month follow-up assessments. All site investigators and practitioners have been
21 vetted and security cleared to work in prisons by HMPPS and have enhanced clearance via the UK
22 Government Disclosure Barring Service. The site investigators have trained all participating
23 practitioners in delivering BFO as CAT and have also conducted training around RCT methodology. All
24 practitioners are trained and experienced facilitators of structured substance misuse interventions.
25 Both site investigators and practitioners have received training in ethics and confidentiality issues
26 when working with offenders in secure settings.

27

1 All prospective participants that potentially meet the study criteria will be informed of the study's
2 objectives and requirements using the Participant Information Sheet and Informed Consent Form
3 before any screening procedures are performed. If willing to participate in the study, participants will
4 be requested to provide written consent after being given sufficient time to consider their
5 participation and having had the opportunity to ask for further details. The Informed Consent Form
6 will be signed and dated by both the participant and the site investigator. The participant will be
7 provided with a copy of the signed consent form and the Participant Information Sheet. The original
8 consent forms will be retained in a secure storage facility separately from source data to protect
9 against breach of privacy and participant anonymity in terms of outcomes.

10

11 If written consent is given, each participant will then be randomized to either the BFO or control group.
12 Randomization will occur at the level of the individual participants, with participants being assigned
13 to one of the study groups following the generation of a random allocation sequence via the *Research*
14 *Randomizer* (from the Social Psychology Network- Urbaniak & Plous, 2011). Sequentially-numbered
15 opaque sealed envelopes containing the treatment group that the participant will be allocated to will
16 be delivered to the research site prior to commencement of the study. The participant number will be
17 determined according to the order of enrolment in the study. The site investigator will assign and open
18 one sealed envelope per participant.

19

20 Following randomization, all participants will be required to complete an assessment with the site
21 investigator to assess study eligibility. A screening log, including the participant number and treatment
22 group assigned by randomization and any subsequent reason/s for exclusion from the study (if
23 applicable), will then be completed by the site investigator.

24

25 No longer than 2-weeks after being randomized and completing the eligibility screening, both study
26 groups will complete a battery of assessments to collect data around primary and secondary outcomes
27 and demographic information including age and ethnicity. This battery of assessment will be delivered

1 digitally via desktop computers within the prison IT suites. The assessment for the BFO group will be
2 completed within the BFO program. The control group will complete the measures via a specially
3 developed digital assessment platform which will deliver the same assessment that is included in the
4 BFO program, but without providing access to any of the digital intervention content provided by BFO.

5

6 Study groups will then complete a period of 4-weeks of substance misuse treatment, of either i) BFO
7 plus standard treatment, or ii) standard treatment only. For the BFO group, the 4-week intervention
8 will be delivered to groups of approximately 10 participants at a time, so it is estimated that
9 approximately 6 – 8 groups will need to run successively in order to achieve the sample size required,
10 in order to account for some attrition between baseline and 4-week post-treatment assessments. BFO
11 group participants will receive two sessions of BFO each week, alongside any standard treatment they
12 may be engaging with.

13

14 Online access to the BFO program is granted via the activation of an access code given to the
15 participant at the alcohol and drug misuse service by authorized practitioners. To activate the access
16 card and create a personal account, the participant must enter a user name and password of his choice
17 along with the access code. The practitioners will be able to assist with the online access if required.

18 The participants must also agree to the Terms & Conditions of using BFO, which are in accordance
19 with the Participant Information Sheet and Informed Consent Form and conform to the European
20 Union General Data Protection Regulation around the use of digitally captured personal data. The
21 practitioners must ensure that they log out of BFO at the end of each treatment session to protect the
22 confidentiality of the data.

23

24 Procedures to enhance retention of participants during the 4-week treatment period will include
25 practitioners providing ongoing support during weekly key-working sessions, which all offenders in
26 the prison will routinely receive during the standard substance misuse treatment. When participants
27 do dropout of the study, new participants will be recruited and randomized to replace dropouts, in

1 order to ensure the required sample size of 120 participants (60 per group) complete the 4-week
2 treatment period and provide post-treatment data. However, in line with ITT principles, all
3 randomized participants, including dropouts, will be included in the final analyses (see 'Data Analysis'
4 section). After completion of the 4-week treatment period, participants in both groups will complete
5 the same battery of digital psychometric assessments on the prison desktop computers.

6

7 Follow-up assessments will then also be completed at 3- and 6-months post-treatment with all
8 participants. Follow-up assessments may be completed either in the community if offenders have
9 been released, or in prison if they are still serving their sentence. Depending on participants'
10 preference, the site investigators will contact all participants who have been released back to the
11 community via telephone or email, and their assessment will be completed either over the phone, or
12 via a link to an online version of the assessment. For those participants who are still serving a prison
13 sentence or have been reconvicted and are serving a new sentence, they will be visited by the site
14 investigator at their current prison and their follow-up assessment will be completed there.

15

16 By following the procedure described above, each participant will take part in the study for a total of
17 approximately 7-months, including 4-weeks of treatment and 3- and 6-month follow-up assessments.

18 It is likely that the study will run for a total of approximately 18-months, which will include enough
19 time for recruitment, running enough successive 4-week long BFO groups to achieve the required
20 sample size, and completion of all 3- and 6-month follow-up assessments.

21

22 **Measures**

23 The primary outcome will be self-reported substance use which will be calculated using answers to
24 two questions i) 'in the last week, how many (unit of measurement) of (substance) did you use on a
25 typical day?', and ii) 'in a typical week, how many days are you using (substance)?'. Given the research
26 setting, i.e. a Category D 'open prison' where offenders spend time in the community each week, it is

1 more likely that any substance use outcomes will be due to genuine treatment effects, than they
2 would be in a more highly secure prison setting with fewer opportunities to access and use substances.

3

4 A number of secondary outcomes will also be measured and will come from standardized
5 psychometric assessments of biopsychosocial functioning, which will include:

6 i) Severity of substance dependence: This will be measured using the Severity of Dependence
7 Scale (SDS; Gossop et al., 1995), which is a 5-item, 4-point Likert scale measuring psychological
8 dependence on illicit drugs, that has been previously used in studies of persistent drug use in
9 prison populations (Strang et al., 2006) and studies of programs to address substance related
10 offending behaviors (Crane & Blud, 2012). It has been demonstrated to have excellent
11 reliability with an alpha coefficient of .89.

12

13 ii) Mental health sequelae: This will be measured using the Patient Health Questionnaire (PHQ-
14 4; Kroenke, Spitzer, Williams, & Löwe, 2009), which is a 4-item, 4-point Likert scale measuring
15 depression and anxiety, which has been demonstrated to have excellent internal reliability
16 (alpha = .81), with scores on the PHQ-4 having been demonstrated to converge with scores
17 on other measures of anxiety and the 20-Item Short Form Health Survey.

18

19 iii) Quality of life: This will be measured using 5 items from the World Health Organization Quality
20 of life measure (WHOQoL-BREF; Skevington, Lotfy, & O'Connell, 2004): A total of 5 items
21 (items 1, 2, 17, 18, 20) from the WHOQoL-BREF have been selected for measuring general
22 quality of life (QoL). Taken as a whole measure, the WHOQoL-BREF is a 26-item, 5-point Likert
23 scale containing items measuring 4 main domains - physical, psychological, social and
24 environmental life satisfaction. As only the first 5 items of the WHOQoL-BREF are being used,
25 internal/external reliability and concurrent validity analyses will be conducted on data
26 generated from these first 5 items in order to ensure reliability and validity of data.

27

1 iv) Biopsychosocial functioning: This will be measured using the Recovery Progression Measure
2 (RPM; Elison, Davies, et al., 2016; Elison, Dugdale, Ward, & Davies, 2017), which is a 36-item
3 measure comprising 6 'impact slider', 11-point Likert scale items each measuring level of
4 severity of impairment in the following 6 domains of functioning; difficult situations, negative
5 thoughts, emotions, unhelpful behaviors, physical sensations, lifestyle. In addition, the RPM
6 contains 30 dichotomous 'yes/no' response items measuring presence or absence of specific
7 biopsychosocial issues within each of the 6 domains. Statistical standardization analyses based
8 on a sample of 2218 service users seeking support for substance misuse found the overall RPM
9 scale to have excellent reliability with an alpha coefficient of .89. The RPM has also been found
10 to be a valid measure with scores from 9208 service users converging significantly with those
11 on standardized psychometric measures of mental health and substance dependence ($p <$
12 .0001).

13

14 In addition to the standardized measures described above, socio-demographic data will also be
15 collected via the digital assessment completed by both study groups, including age and ethnicity.
16 Additional socio-demographic data will be collected via paper/pen assessment when participants are
17 first randomized, including educational level achieved, employment status before entering prison, and
18 marital status (See Appendix A), and what standard treatments each participant has received (see
19 Appendix B). This will allow comparisons of the two study groups to be made, and also comparisons
20 of all participants with the broader prison population.

21

22 When follow-up assessments are conducted at 3- and 6-months, each offender will also be asked
23 about any further involvement with criminal justice authorities since being released from prison, if
24 they have been released from prison in the interim, and if so, the nature of this involvement with the
25 authorities, e.g. being arrested, any court appearances etc. (See Appendix C). For ethical and legal
26 reasons, these questions will be restricted to questions that enquire as to criminal justice system

1 involvement only, as opposed to asking participants about any crimes they may have committed that
2 may not have been discovered by the authorities.

3

4 **Data analysis**

5 Quantitative data will be analyzed and reported using SPSS® Version 25.0 (or later) with all analyses
6 to be performed as per the statistical analysis plan. The appropriate 95% - confidence interval will be
7 applied. The *all-randomized population* will consist of all participants in the study that have completed
8 the Screening Visit and have been allocated to either the i) BFO plus standard treatment, or, ii)
9 standard treatment only group. The *per-protocol population* will consist of all participants randomized
10 into the study who have completed the 4-week treatment period as well as all follow-up assessments.

11

12 Interim and final analyses will be performed on the basis of an ITT population, with the all-randomized
13 population included in the analyses. No participants will be excluded from the ITT analyses, i.e. those
14 who have withdrawn, been lost to follow-up, or have provided incomplete outcomes data. Separate
15 analyses will also be conducted on the per-protocol population who have provided at least one set of
16 follow-up data. Outcomes from these two analyses (ITT, per-protocol population) will be compared to
17 examine whether missing data may have had an impact on reliability of conclusions formed around
18 comparative effectiveness of the two study conditions (i. BFO plus standard treatment, ii. Standard
19 treatment only.

20

21 Previous analyses (Elison, Davies, et al., 2015a, 2015b; Elison, Weston, et al., 2015) indicate that data
22 will likely be non-normally distributed in which case nonparametric Analyses of Covariance (ANCOVA)
23 using appropriate distribution such as Poisson distribution, will be used to compare the study groups
24 at 4-weeks post-treatment and 3- and 6-months follow-up on self-reported substance use, substance
25 dependence, mental health sequelae, biopsychosocial functioning and quality of life. However,
26 normality will be tested when data are available for analyses, and appropriate distributions will be
27 applied. Specialist statistical support will be sought from colleagues at one of the collaborating

1 academic institutions (University of Manchester). When analyzing differences between the two study
2 groups at each of the outcomes data time-points, (4-weeks post-treatment, 3- and 6-month follow-
3 ups) baseline scores will be controlled for as post-treatment between-group differences may reflect
4 both treatment effects and also group differences at baseline that randomization may not have
5 addressed. Differences between the groups in post-treatment scores will be ascertained using
6 estimated marginal means.

7

8 Effect sizes will also be calculated to examine robustness of between-group differences and within-
9 group changes over time, using partial eta squared (η^2), which is an appropriate measure of effect size
10 for ANCOVA. The numbers of participants fulfilling clinical threshold scores for substance dependence,
11 depression and anxiety at baseline and post-treatment will also be examined.

12

13 Interim analyses will be performed on the first 30 participants of each group to have completed the
14 3- and 6-months follow-up after treatment completion. Attrition in each study group and equivalence
15 of study group characteristics at baseline will be taken into account, in addition to outcomes in order
16 to ascertain whether there are significant differences between the two groups at the study mid-point.
17 An interim report will be issued prior to completion of the study and a final report will be issued and
18 submitted to the ethics committee within 6-months of completion of the study.

19

20 **Power calculation**

21 Since the study is a parallel-group comparison, equal numbers of participants will be required for each
22 of the groups; i) BFO plus standard treatment, and, ii) standard treatment only. The study projection
23 of the sample size will require 60 evaluable participants in each treatment group to achieve enough
24 power (assuming power of 0.80 with $\alpha = .05$) with an allowance of 50% attrition at 3- and 6-months
25 follow-up, which is in line with previous studies with offender populations receiving interventions for
26 substance misuse in correctional settings (e.g. Crisanti, Case, Isakson, & Steadman, 2014). In addition,
27 this level of attrition is also seen in substance misuse intervention research more generally (e.g.

1 Brorson, Ajo Arnevik, Rand-Hendriksen, & Duckert, 2013) and in many digital interventions studies
2 (e.g. Eysenbach, 2005). To obtain a total of 120 evaluable participants, it is estimated 240 participants
3 will need to be recruited and screened. The sample size may be recalculated after an interim analysis
4 when data for 30 evaluable participants per treatment group are available.

5

6 These estimations have been based on previous samples used for assessments of CAT (Carroll et al.,
7 2008), some of which have used longitudinal statistical analyses (Koski-Jännes, Cunningham, &
8 Tolonen, 2009; Kypri, Langley, Saunders, Cashell-Smith, & Herbison, 2008). It is envisaged that the
9 estimated evaluable participant population will be sufficiently large to enable meaningful descriptive
10 comparisons to be performed. However, these participation numbers may be subject to alterations
11 depending on the interim analyses which will be performed.

12

13 **Discussion**

14 This protocol describes the methodology for an RCT to examine the efficacy of a CAT program for
15 substance-involved offenders, Breaking Free Online (BFO) Health and Justice, when delivered
16 alongside standard treatment, compared with standard treatment only, in a prison setting. This
17 program is the first digital offender management program to be accredited and commissioned by the
18 UK Ministry of Justice, and to date, this is the first RCT of a digital treatment program for offenders to
19 be conducted within the UK prison estate.

20

21 Published research examining effectiveness of both the community treatment setting version of the
22 program (Elison, Davies, et al., 2015a, 2015b) and the criminal justice setting version described in this
23 protocol (Davies et al., 2017; Elison, Weston, et al., 2015) has suggested that the program may be
24 effective in supporting substance misusing individuals to significantly reduce their substance use and
25 dependence. In addition, the program may significantly reduce the severity of mental health
26 difficulties and biopsychosocial impairment and improve quality of life (Elison, Ward, Davies,
27 Lidbetter, et al., 2014; Elison, Ward, et al., 2017).

1

2 Other published research has examined mechanisms of action of BFO in a sample of participants
3 engaging with the program in community-based treatment settings (Elison, Jones, et al., 2017), which
4 has demonstrated the primacy of cognitive change to instigating behavioral change. Completion of
5 cognitive restructuring strategies in the program has been demonstrated to be associated with
6 multiple aspects of behavioral and biopsychosocial improvements. In addition, this research has
7 demonstrated that individuals using BFO follow tailoring advice provided by the program, which
8 suggests that users spend more time working on intervention strategies associated with domains of
9 biopsychosocial functioning that they might be experiencing greater levels of impairment. Therefore,
10 for the group in this RCT who will be engaging with BFO alongside standard treatment, the
11 mechanisms of action analyses conducted will be replicated, to examine the mechanisms of action of
12 the program when implemented in criminal justice settings.

13

14 Potential limitations of the methodology include the fact that it will be difficult for the investigators
15 or the practitioners working in the prison substance misuse service to be blinded to the allocation of
16 participants to each of the two study groups. This is because the investigators will have to randomize
17 participants and then organize the BFO groups in the prison, and so they will need to know which
18 group each participant is randomized to in order to do this. Although the practitioners will not
19 immediately know which group each participant has been allocated to, very shortly after
20 randomization they will receive a list of all offenders in the BFO group. This is because they will need
21 to check attendance to the group, which is particularly important in a secure prison environment in
22 which the whereabouts of individual offenders must be accounted for at all times. It is also a
23 requirement of prison regimes in the UK for any member of staff facilitating a group session to know
24 ahead of the session which offenders will be attending. This is so staff can be aware ahead of the
25 session of any special circumstances surrounding each offender that may need to be taken into
26 account or may pose a risk for any reason, for example if a specific offender had recently had any
27 emotional or behavioral difficulties etc.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Another limitation lies in the fact that the level of randomization is at the level of individual offenders, which means that intervention group participants and control group participants will have the opportunity to interact with one another within the prison. This may result in members of the intervention group discussing content of BFO with control group participants, which may contaminate the outcomes and violate the stable unit treatment value assumption. However, this study has to be conducted in a very specific kind of prison environment, which limited the number of potential research sites and made the option of randomization at the level of the research site impractical. Indeed, recruiting prisons to participate in research is difficult generally, given the unique challenges faced within such secure environments and the additional challenges posed by issues such as understaffing in most UK prisons – this makes it difficult for prisons to participate in additional activities outside of the core prison regime. And from a methodological perspective, the study has to be conducted in an open prison where participants may conceivably have an opportunity to continue to use substances, although the authors note there is still significant illicit substance use in the UK and other countries, even in high-secure prisons.

Finally, a significant limitation may lie with the possible attrition rates that may be expected from a study that includes substance-involved offenders as participants, as it can be particularly difficult to maintain engagement with individuals who may have issues around substance misuse and offending. Although measures can be put in place to enhance retention of participants whilst they are still serving their prison sentence, such as weekly key-working sessions with practitioners as part of standard treatment, it may be particularly challenging to retain participants in the study once they are released back to the community. Every attempt will be made to contact participants and obtain follow-up data, and it is hoped that as most participants will be in contact with probation services, this may provide a means of contacting participants as they complete their sentence in the community.

1 **Declarations**

2 **Abbreviations**

3 ANCOVA - analysis of covariance; ANOVA - analysis of variance; CAT - computer-assisted therapy; CBT
4 - cognitive-behavioural therapy; HMPPS - Her Majesty's Prison and Probation Service; ITT - intention
5 to treat; LBM - Lifestyle Balance Model; NICE - National Institute of Health and Care Excellence; PHQ -
6 Patient Health Questionnaire; QoL - quality of life; RCT - randomised controlled trial; RPM - Recovery
7 Progression Measure; SDS - Severity of Dependence Scale; VC - Virtual Campus; WHOQoL-BREF -
8 World Health Organisation Quality of Life Scale.

9

10 **Ethics approval and consent to participate**

11 Ethical approval for an amended version of this protocol, for which ethical approval had already been
12 granted, was granted by the North West – Greater Manchester West Research Ethics Committee on
13 30.08.2017 (REC Ref: 17/NW/0422). Participants must have provided informed consent, via reading
14 the Participant Information Sheet and signing the Consent Form, before they can take part in the
15 study.

16

17 **Consent for publication**

18 Not applicable

19

20 **Availability of data and materials**

21 Requests for anonymised datasets and access to the materials contained within Breaking Free Online
22 Health and Justice will be considered upon request in writing to the authors.

23

24 **Funding**

25 No funding has been provided for this study.

26

27 **Acknowledgements**

1 The authors would like to extend their thanks to all the service users and staff from both criminal
2 justice and community substance misuse treatment settings who have assisted with the development
3 and evaluation of Breaking Free Online to date.

4

5 **References**

- 6 American Psychiatric Association. (2000). *Diagnostic and Statistical Manual of Mental Disorders- Text*
7 *Revision (DSM-IV-TR)*. In.
- 8 Ball, J. C., Shaffer, J. W., & Nurco, D. N. (1983). The day to-day criminality of heroin addicts in
9 Baltimore—A study in the continuity of offence rates. *Drug and alcohol dependence, 12(2)*,
10 119-142.
- 11 Beck, A. T. (1993). Cognitive therapy: past, present, and future. *J Consult Clin Psychol, 61*.
12 doi:10.1037/0022-006x.61.2.194
- 13 Beck, A. T., Wright, F. D., Newman, C. F., & Liese, B. S. (2011). *Cognitive therapy of substance abuse*.
14 London: Guilford Press.
- 15 Bennett, T., & Holloway, K. (2009). The causal connection between drug misuse and crime. *British*
16 *Journal of Criminology, 49(4)*, 513-531.
- 17 Bennett, T., Holloway, K., & Farrington, D. (2008). The statistical association between drug misuse
18 and crime: A meta-analysis. *Aggression and Violent Behavior, 13(2)*, 107-118.
- 19 Best, D., Sidwell, C., Gossop, M., Harris, J., & Strang, J. (2001). Crime and Expenditure amongst
20 Polydrug Misusers Seeking Treatment The Connection between Prescribed Methadone and
21 Crack Use, and Criminal Involvement. *British Journal of Criminology, 41(1)*, 119-126.
- 22 Bickel, W. K., Marsch, L. A., Buchhalter, A. R., & Badger, G. J. (2008). Computerized behavior therapy
23 for opioid-dependent outpatients: A randomized controlled trial. *Experimental and Clinical*
24 *Psychopharmacology, 16(2)*, 132-143.
- 25 Boden, J. M., Fergusson, D. M., & Horwood, L. J. (2012). Alcohol misuse and violent behavior:
26 findings from a 30-year longitudinal study. *Drug & Alcohol Dependence, 122(1)*, 135-141.

- 1 Brorson, H. H., Ajo Arnevik, E., Rand-Hendriksen, K., & Duckert, F. (2013). Drop-out from addiction
2 treatment: A systematic review of risk factors. *Clinical Psychology Review, 33*(8), 1010-1024.
3 doi:<https://doi.org/10.1016/j.cpr.2013.07.007>
- 4 Budd, T., Collier, P., Mhlanga, B., Sharp, C., & Weir, G. (2005). *Levels of self-report offending and drug*
5 *use among offenders: Findings from the Criminality Surveys*: Home Office London.
- 6 Carroll, K., Ball, S., Martino, S., Nich, C., Babuscio, T., Nuro, K., . . . Rounsaville, B. (2008). Computer-
7 assisted delivery of cognitive-behavioral therapy for addiction: A randomized trial of
8 CBT4CBT. *American Journal of Psychiatry, 165*(7), 881-888.
- 9 Comiskey, C. M., Stapleton, R., & Kelly, P. A. (2012). Ongoing cocaine and benzodiazepine use:
10 Effects on acquisitive crime committal rates amongst opiate users in treatment. *Drugs:*
11 *Education, Prevention and Policy, 19*(5), 406-414.
- 12 Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., & Petticrew, M. (2008). Developing and
13 evaluating complex interventions: the new Medical Research Council guidance. *British*
14 *Medical Journal, 337*(sep29_1), a1655-a1655.
- 15 Crane, M. A. J., & Blud, L. (2012). The effectiveness of Prisoners Addressing Substance Related
16 Offending (P-ASRO) programme: evaluating the pre and post treatment psychometric
17 outcomes in an adult male Category C prison. *British Journal of Forensic Practice, 14*(1), 49-
18 59.
- 19 Crisanti, A. S., Case, B. F., Isakson, B. L., & Steadman, H. J. (2014). Understanding study attrition in
20 the evaluation of jail diversion programs for persons with serious mental illness or co-
21 occurring substance use disorders. *Criminal Justice and Behavior, 41*(6), 772-790.
- 22 Davies, G., Elison, S., Ward, J., & Laudet, A. (2015). The role of lifestyle in perpetuating substance
23 dependence: A new explanatory model, The Lifestyle Balance Model. *Substance Abuse,*
24 *Treatment, Prevention and Policy, 10*(2), e1-18.
- 25 Davies, G., Ward, J., Elison, S., Weston, S., Dugdale, S., & Weekes, J. (2017). Implementation and
26 evaluation of the Breaking Free Online and Pillars of Recovery treatment and recovery

1 programmes for substance-involved offenders: Reflections from the North-West Prisons
2 'Gateways' pathfinder. *Advancing Corrections*(3), 95-113.

3 Dugdale, S., Elison, S., Davies, G., Ward, J., & Dalton, M. (2017). A qualitative study investigating the
4 continued adoption of Breaking Free Online across a national substance misuse
5 organisation: Theoretical conceptualisation of staff perceptions. *The Journal of Behavioral*
6 *Health Services and Research*, 44(1), 89-101.

7 Dugdale, S., Elison, S., Ward, J., Davies, G., & Dalton, M. (2016). Using the Transtheoretical Model to
8 explore the impact of peer mentoring on peer mentors' own recovery from substance
9 misuse. *Journal of Groups in Addiction and Recovery*, 11(3), 166-181.

10 Dugdale, S., Ward, J., Hernen, J., Elison, S., Davies, G., & Donkor, D. (2016). Using the Behavior
11 Change Technique Taxonomy v1 to conceptualize the clinical content of Breaking Free
12 Online: a computer-assisted therapy program for substance use disorders. *Substance abuse*
13 *treatment, prevention, and policy*, 11(1), 26.

14 Elison, S., Davies, G., & Ward, J. (2015a). Effectiveness of Computer-Assisted Therapy for Substance
15 Dependence Using Breaking Free Online: Subgroup Analyses of a Heterogeneous Sample of
16 Service Users. *Journal of medical Internet research*, 2(2), e13.

17 Elison, S., Davies, G., & Ward, J. (2015b). An outcomes evaluation of computerised treatment for
18 problem drinking using Breaking Free Online *Alcoholism Treatment Quarterly*, 33(2), 185-
19 196.

20 Elison, S., Davies, G., & Ward, J. (2016). Initial development and psychometric properties of a new
21 measure of substance misuse 'recovery progression': The Recovery Progression Measure
22 (RPM). *Substance Use and Misuse*, 51(9), 1195-1206.

23 Elison, S., Davies, G., Ward, J., Weston, S., Dugdale, S., & Weekes, J. (2017). Using the "recovery" and
24 "rehabilitation" paradigms to support desistance of substance-involved offenders:
25 exploration of dual and multi-focus interventions. *Journal of Criminological Research, Policy*
26 *and Practice*, 2(4), 274-290.

- 1 Elison, S., Dugdale, S., Ward, J., & Davies, G. (2017). The 'Rapid Recovery Progression Measure'
2 (rapid-RPM) a brief assessment of psychosocial functioning change during problematic
3 substance use recovery progression. *Substance Use and Misuse*, 52(9), 1160-1169.
- 4 Elison, S., Jones, A., Ward, J., Dugdale, S., & Davies, G. (2017). Examining effectiveness of tailorable
5 computer-assisted therapy programmes for substance misuse: Programme usage and clinical
6 outcomes data from Breaking Free Online. *Addictive Behaviors*, 74, 140-147.
- 7 Elison, S., Ward, J., Davies, G., Lidbetter, N., Dagley, M., & Hulme, D. (2014). An outcomes study of
8 eTherapy for dual diagnosis using Breaking Free Online. *Advances in Dual Diagnosis*, 7(2), 52-
9 62.
- 10 Elison, S., Ward, J., Davies, G., & Moody, M. (2014). Implementation of computer-assisted therapy
11 for substance misuse: a qualitative study of Breaking Free Online using Roger's diffusion of
12 innovation theory. *Drugs and Alcohol Today*, 14(4), 207-218.
- 13 Elison, S., Ward, J., Williams, C., Espie, C., Davies, G., Dugdale, S., . . . Smith, K. (2017). Feasibility of a
14 UK community-based, eTherapy mental health service in Greater Manchester: repeated-
15 measures and between-groups study of 'Living Life to the Full Interactive', 'Sleepio' and
16 'Breaking Free Online' at 'Self Help Services'. *BMJ Open*, 7(7), 1-10.
- 17 Elison, S., Weston, S., Davies, G., Dugdale, S., & Ward, J. (2015). Findings from mixed-methods
18 feasibility and effectiveness evaluations of the "Breaking Free Online" treatment and
19 recovery programme for substance misuse in prisons. *Drugs: Education, Prevention and*
20 *Policy*, 23(2), 1-10.
- 21 Elison, S., Weston, S., Dugdale, S., Ward, J., & Davies, G. (2016). A qualitative exploration of UK
22 prisoners' experiences of substance misuse and mental health difficulties, and the Breaking
23 Free Health and Justice interventions. *Journal of Drug Issues*, 46(3), 198-215.
- 24 Eysenbach, G. (2005). The law of attrition. *Journal of medical Internet research*, 7(1).
- 25 Fazel, S., Yoon, I. A., & Hayes, A. J. (2017). Substance use disorders in prisoners: an updated
26 systematic review and meta-regression analysis in recently incarcerated men and women.
27 *Addiction*, 112(10), 1725-1739.

- 1 Goldstein, P. J. (1985). The drugs/violence nexus: A tripartite conceptual framework. *Journal of Drug*
2 *Issues*.
- 3 Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The Severity of
4 Dependence Scale (SDS): psychometric properties of the SDS in English and Australian
5 samples of heroin, cocaine and amphetamine users. *Addiction, 90*(5), 607-614.
- 6 Gossop, M., Marsden, J., Stewart, D., & Rolfe, A. (2000). Reductions in acquisitive crime and drug use
7 after treatment of addiction problems: 1-year follow-up outcomes. *Drug and alcohol*
8 *dependence, 58*(1), 165-172.
- 9 Greenberger, D., & Padesky, C. A. (1995). *Mind over mood: Change how you feel by changing the*
10 *way you think*: The Guilford Press.
- 11 Hayhurst, K. P., Jones, A., Millar, T., Pierce, M., Davies, L., Weston, S., & Donmall, M. (2013). Drug
12 spend and acquisitive offending by substance misusers. *Drug & Alcohol Dependence, 130*(1),
13 24-29.
- 14 Home Office. (2016). Drug Misuse: Findings from the 2015/16 Crime Survey for England and Wales:
15 Second edition In. London: Home Office.
- 16 Hough, M. (2002). Drug user treatment within a criminal justice context. *Substance Use & Misuse,*
17 *37*(8-10), 985-996. doi:doi:10.1081/JA-120004162
- 18 Inciardi, J. A. (1979). Heroin use and street crime. *Crime & Delinquency, 25*(3), 335-346.
- 19 Jones, A., Weston, S., Moody, A., Millar, T., Dollin, L., Anderson, T., & Donmall, M. (2007). The drug
20 treatment outcomes research study (DTORS): baseline report In. London: Home Office.
- 21 Koski-Jännes, A., Cunningham, J., & Tolonen, K. (2009). Self-assessment of drinking on the Internet—
22 3-, 6-and 12-month follow-ups. *Alcohol and alcoholism, 44*(3), 301-305.
- 23 Kroenke, K., Spitzer, R. L., Williams, J. B., & Löwe, B. (2009). An ultra-brief screening scale for anxiety
24 and depression: The PHQ-4. *Psychosomatics, 50*(6), 613-621.
- 25 Kypri, K., Langley, J. D., Saunders, J. B., Cashell-Smith, M. L., & Herbison, P. (2008). Randomized
26 controlled trial of web-based alcohol screening and brief intervention in primary care.
27 *Archives of Internal Medicine, 168*(5), 530-536.

- 1 Lundholm, L., Haggård, U., Möller, J., Hallqvist, J., & Thiblin, I. (2013). The triggering effect of alcohol
2 and illicit drugs on violent crime in a remand prison population: a case crossover study. *Drug*
3 *& Alcohol Dependence*, 129(1), 110-115.
- 4 Marlatt, G., Bowen, S., Chawla, N., & Witkiewitz, K. (2010). Mindfulness-based relapse prevention for
5 substance abusers: Therapist training and therapeutic relationships. In Z. Segal, S. Hick, & T.
6 Bien (Eds.), *Mindfulness and the therapeutic relationship*: The Guilford Press.
- 7 Marlatt, G. A., & Donovan, D. M. (2005). *Relapse prevention: Maintenance strategies in the*
8 *treatment of addictive behaviors*: Guilford Press.
- 9 McGlothlin, W. H., Anglin, M. D., & Wilson, B. D. (1978). Narcotic addiction and crime. *Criminology*,
10 16(3), 293-316.
- 11 Michie, S., Hyder, N., Walia, A., & West, R. (2011). Development of a taxonomy of behaviour change
12 techniques used in individual behavioural support for smoking cessation. *Addictive*
13 *Behaviors*, 36(4), 315-319.
- 14 Moore, B. A., Fazzino, T., Garnet, B., Cutter, C. J., & Barry, D. T. (2011). Computer-based
15 interventions for drug use disorders: A systematic review. *Journal of substance abuse*
16 *treatment*, 40(3), 215-223.
- 17 Moore, G. F., Audrey, S., Barker, M., Bond, L., Bonell, C., Hardeman, W., . . . Baird, J. (2015). Process
18 evaluation of complex interventions: Medical Research Council guidance. *Bmj*, 350.
19 doi:10.1136/bmj.h1258
- 20 National Treatment Agency for Substance Misuse. (2006a). Models of care for treatment of adult
21 drug misusers: Update 2006. In NHS (Ed.).
- 22 National Treatment Agency for Substance Misuse. (2006b). Review of the effectiveness of treatment
23 for alcohol problems. Retrieved from
24 http://www.nta.nhs.uk/uploads/nta_review_of_the_effectiveness_of_treatment_for_alcohol_problems_fullreport_2006_alcohol2.pdf
- 25
26 NICE. (2007). Drug misuse in over 16s: psychosocial interventions: Clinical guideline [CG51]. In.
27 London.

- 1 NICE. (2011). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and
2 alcohol dependence. In *Clinical guideline [CG115]*.
- 3 NICE. (2012). Drug use disorders in adults: Quality standard [QS23]. In. London.
- 4 PHE. (2016). The Public Health Burden of Alcohol and the Effectiveness and Cost-Effectiveness of
5 Alcohol Control Policies: An evidence review. In. London: Public Health England.
- 6 PHE. (2017). Adult substance misuse statistics from the National Drug Treatment Monitoring System
7 (NDTMS) - 1 April 2016 to 31 March 2017. In N. D. E. C. U. o. Manchester (Ed.). London:
8 Department of Health.
- 9 Phillips, P. (2000). Substance misuse, offending and mental illness: a review. *Journal of Psychiatric
10 and Mental Health Nursing, 7*(6), 483-489. doi:10.1046/j.1365-2850.2000.00334.x
- 11 Schroeder, R. D., Giordano, P. C., & Cernkovich, S. A. (2007). Drug use and desistance processes.
12 *Criminology, 45*(1), 191-222.
- 13 Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004). The World Health Organization's WHOQOL-
14 BREF quality of life assessment: psychometric properties and results of the international
15 field trial. A report from the WHOQOL group. *Quality of Life Research, 13*(2), 299-310.
- 16 Solis, J. M., Shadur, J. M., Burns, A. R., & Hussong, A. M. (2012). Understanding the Diverse Needs of
17 Children whose Parents Abuse Substances. *Current drug abuse reviews, 5*(2), 135-147.
- 18 Strang, J., Gossop, M., Heuston, J., Green, J., Whiteley, C., & Maden, A. (2006). Persistence of drug
19 use during imprisonment: relationship of drug type, recency of use and severity of
20 dependence to use of heroin, cocaine and amphetamine in prison. *Addiction, 101*(8), 1125-
21 1132.
- 22 Stuart, G. L., Temple, J. R., Follansbee, K. W., Bucossi, M. M., Hellmuth, J. C., & Moore, T. M. (2008).
23 The role of drug use in a conceptual model of intimate partner violence in men and women
24 arrested for domestic violence. *Psychology of addictive behaviors, 22*(1), 12.
- 25 Urbaniak, G., & Plous, S. (2011). Research randomizer (version 3.0)[Computer software]. Retrieved
26 on April 22, 2011. In.


1 Ward, J., Davies, G., Dugdale, S., Elison, S., & Bijral, P. (2017). Achieving digital health sustainability:
 2 Breaking Free and CGL. *International Journal of Health Governance*, 22(2), 72-82.

3 Weekes, J., Moser, A., & Langevin, C. (1999). Assessing substance abusing offenders for treatment. In
 4 E. Latessa (Ed.), *Strategic Solutions: The International Community Corrections Association*
 5 *Examines Substance Abuse*. Lanham, MD: American Correctional Association.

6 Williams, C., & Chellingsworth, M. (2010). *CBT: A Clinician's Guide to Using the Five Areas Approach*.
 7 London: Hodder Arnold.

8 Wilson, I. M., Graham, K., & Taft, A. (2017). Living the cycle of drinking and violence: A qualitative
 9 study of women's experience of alcohol-related intimate partner violence. *Drug and alcohol*
 10 *review*, 36(1), 115-124.

11 Young, S., Wells, J., & Gudjonsson, G. (2011). Predictors of offending among prisoners: the role of
 12 attention-deficit hyperactivity disorder and substance use. *Journal of Psychopharmacology*,
 13 25(11), 1524-1532.



14
 15 **Figure 1: The Lifestyle Balance Model**

16
 17
 18

1 **Table 1: Breaking Free Online content**

2

Strategies included in Breaking Free Online	Description of strategy	Therapeutic approaches underpinning strategies	BCT taxonomy (V1) techniques (number in taxonomy)
Lifestyle balance model (individualized diagram)	Generic formulation; Idiosyncratic formulation; Personalized feedback; Case formulation – understand the links between situations, thoughts, emotions, behaviors, physical sensations and lifestyle	Node-link mapping (International Treatment Effectiveness Program (ITEP); Cognitive-behavioral therapy (CBT)	Information about antecedents (4.2); Information about health consequences (5.1); Salience of consequences (5.2); Information about social and environmental consequences (5.3); Information about emotional consequences (5.6)
Understanding your difficult situations	Assessment; Self-monitoring; Standardized measures; Psycho-education on impact of problematic situations; Intervention to help people in distress access support	All structured therapeutic approaches; Psycho-education; Guided self-help	Social support (unspecified) (3.1); Reduce negative emotions (11.2)
Managing your risky situations: Recognize–avoid–cope	Recognize–avoid–cope; Relapse prevention for coping with environmental/situational/emotional triggers; Creating action plans on how to avoid or cope in high risk situations	Relapse prevention; Refusal skills	Problem solving (1.2); Action planning (1.4); Instruction on how to perform a behavior (4.1); Behavioral practice/rehearsal (8.1); Behaviour substitution (8.2); Avoidance/reducing exposure to cues for the behavior (12.3); Goal setting (behavior) (1.1); Problem solving (1.2); Action planning (1.4)
Understanding your negative thoughts	Psycho-education on impact on negative thoughts	Psycho-education; Guided self-help	Information about antecedents (4.2); Information about health consequences (5.1); Salience of consequences (5.2); Information about social and environmental consequences (5.3); Information about emotional consequences (5.6)
Escaping your mind traps	Mind traps; Cognitive restructuring; Challenge thoughts that may be unhelpful	International Treatment Effectiveness Program (ITEP); Cognitive-behavioral therapy (CBT)	Re-attribution (4.3); Framing-reframing (13.2)
Understanding your emotions	Psycho-education on impact on emotions	Psycho-education; Guided self-help	Information about antecedents (4.2); Information about health consequences (5.1); Salience of consequences (5.2); Information about social and environmental consequences (5.3); Information about emotional consequences (5.6)

Shifting your focus	Attention narrowing; Attention switching; Emotional regulation; Recognize/understand/normalize emotions; Developing more appropriate coping strategies	Coping strategy enhancement (CSE); Mindfulness-based cognitive therapy	Information about emotional consequences (5.6); Behavioral practice/rehearsal (8.1); Reduce negative emotions (11.2); Problem solving (1.2); Social support (unspecified) (3.1); Behavioral practice/rehearsal (8.1); Distraction (12.4)
Understanding your physical sensations	Psycho-education on impact of physical sensations	Psycho-education; Guided self-help	Information about antecedents (4.2); Information about health consequences (5.1); Salience of consequences (5.2); Information about social and environmental consequences (5.3); Information about emotional consequences (5.6)
Surfing your cravings and urges	Urge surfing; Body scanning; Relapse prevention-based techniques	Mindfulness-based cognitive therapy	Instruction on how to perform a behavior (4.1); Behavioral practice/rehearsal (8.1); Reduce negative emotions (11.2)
Understanding your unhelpful behaviors	Psycho-education on impact of destructive behaviors	Psycho-education; Guided self-help	Information about antecedents (4.2); Information about health consequences (5.1); Salience of consequences (5.2); Information about social and environmental consequences (5.3); Information about emotional consequences (5.6)
Planning your time positively	Activity scheduling; Behavioral activation; Encourage new behaviors via positive feedback; Increase activity to increase energy levels and relieve boredom	Cognitive-behavioral therapy (CBT)	Non-specific reward (10.3); Non-specific incentive (10.6); Reward approximation (14.4); Rewarding completion (14.5); Goal setting (behavior) (1.1); Action planning (1.4)
Understanding your lifestyle	Psycho-education on impact of lifestyle; Creating SMART goals for recovery	Psycho-education; Guided self-help	Goal setting (behavior) (1.1); Problem solving (1.2); Goal setting (outcome) (1.3); Action planning (1.4)
Achieving your life goals	Goal-setting Increase treatment engagement and retention. Increase readiness to change behavior	Motivational enhancement therapy (MET); Implementation intentions	Non-specific reward (10.3); Focus on past success (15.3); Action planning (1.4)
Progress check	Monitor behavior to provide feedback about progress towards goals; Encourage new behaviors via positive feedback	Self-monitoring	Self-monitoring of behavior (2.3); Feedback on outcome(s) of behavior (2.7)
Information on alcohol and drugs	Psycho-education on effects of alcohol and drugs; Reduce negative or fatal consequences of substance using behaviors	Harm reduction; Psycho-education	Information about health consequences (5.1); Salience of consequences (5.2); Behaviour substitution (8.2); Habit reversal (8.4)

1 **Appendix A: Additional socio-demographic questions**

2 **1. What is your date of birth?**

3

4 **2. What is your marital status?**

5 Married / civil partnership

6 Single

7 Divorced / separated

8 Widowed

9 Living with partner

10

11 **3. What was your occupation before you came to prison (select more than one response if**
12 **applicable)?**

13 In full-time employment (specify)

14 In part-time employment (specify)

15 In full-time education (specify)

16 In part-time education (specify)

17 Full-time carer

18 Unemployed

19 Other (specify)

20

21 **4. At what level did you finish full-time education?**

22 Primary school

23 Secondary school

24 Further education (i.e. course of study after secondary school level education)

25 Higher education (i.e. undergraduate or postgraduate university course of study)

26 No formal education

27 Other (specify)

1

2 **Appendix B: Standard treatment questions**

3 **1. Which of the following treatments for your drug or alcohol difficulties did you receive**
4 **whilst during your participating in the study?**

5 Prescribed substitute medication

6 Medication for detox

7 Mental health medication e.g. antidepressants

8 One to one key-working

9 Structured group intervention delivered by practitioners

10 Mutual aid group work e.g. AA, NA, SMART

11 Complementary therapies, e.g. acupuncture

12

13 **2. What kind of practitioners have provided you with support during your participating in the**
14 **study?**

15 Recovery workers/ drug workers

16 Medical professional e.g. Psychiatrist, GP

17 Nurse/ Mental health nurse

18 Psychologist/ counsellor

19 Offender manager

20 Listeners/ peer mentors

21

22 **3. How often did you receive support from practitioners during your participation in the**
23 **study?**

24 Every day

25 Several days each week

26 One day each week

27 Several days each month Once a month

1 Less than once a month

2

3 **Appendix C: Further criminal justice system involvement questions (for participants who have**
4 **been released from prison at 3- or 6-month follow-up).**

5 We would like to ask you about any involvement you may have had with criminal justice authorities
6 since we last spoke to you. You do not have to tell us about any crimes you may have committed
7 that are not currently being dealt with by criminal justice authorities:

8 1. Have you been re-arrested since completing your last prison sentence?

9

10 2. Have you had attended any more court appearances related to offenses you have been
11 accused of committing since completing your last prison sentence?

12

13 3. Have you been convicted of any new offences since you completed your last prison
14 sentence?

15

16 4. Have you been recalled to prison since completing your last prison sentence?

17

18